Characteristic | β (95% CI) | p |
---|---|---|
Femoral neck | ||
Transitional menstrual status | −0.460 (−1.632, 0.712) | 0.439 |
New organ damage | −2.417 (−4.526, −0.308) | 0.025* |
Antiosteoporosis therapies | 3.397 (0.797, 5.996) | 0.011* |
Total hip | ||
Transitional menstrual status | −0.526 (−1.570, 0.517) | 0.319 |
Flare during followup | −1.262 (−3.662, 1.138) | 0.300 |
New organ damage | −1.667 (−3.607, 0.274) | 0.092 |
Daily oral glucocorticoids ≥ 7.5 mg for ≥ 3 mos | −0.614 (−3.406, 2.178) | 0.664 |
Cumulative dose of glucocorticoids | −0.073 (−0.286, 0.141) | 0.502 |
Antiosteoporosis therapies | 3.729 (1.389, 6.070) | 0.002* |
Lumbar spine | ||
Transitional menstrual status | −1.808 (−3.259, −0.357) | 0.015* |
25[OH]D level | 0.116 (−0.021, 0.254) | 0.097 |
Flare during followup | −1.342 (−4.390, 1.584) | 0.385 |
Oral glucocorticoids | −6.307 (−14.197, 1.584) | 0.116 |
Cumulative dose of glucocorticoids | −0.432 (−0.887, 0.022) | 0.062 |
Cumulative duration of glucocorticoids | 0.150 (−0.010, 0.310) | 0.065 |
Antiosteoporosis therapies | 6.048 (2.796, 9.301) | < 0.0005* |
↵* Statistically significant. 25[OH]D: 25-hydroxy Vitamin D.